Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

13.36 -0.36 (-2.66%)
Streaming Delayed Price Updated: 12:41 PM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 Next >
News headline image
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
Issued on behalf of Helus Pharma (Nasdaq: HELP) 
From USA News Group
Via GlobeNewswire
News headline image
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Elects Kathleen Tregoning to Board of Directors
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments
From Compass Pathfinder Limited
Via Business Wire
News headline image
Small-Cap Medical Stocks: ATAI, CMPS, NDRA, PBM in Focus as U.S. Policy Accelerates Psychedelic Research
Via AB Newswire
News headline image
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026
From Compass Pathfinder Limited
Via Business Wire
News headline image
Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants
From Compass Pathfinder Limited
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>